Koyfin Home > Directory > Health Care > Acceleron Pharma > Long-Term Debt / Capital

Acceleron Pharma Long-Term Debt / Capital Chart (XLRN)

Acceleron Pharma annual/quarterly Long-Term Debt / Capital from 2012 to 2020.
  • Acceleron Pharma Long-Term Debt / Capital for the quarter ending June 06, 2020 was $4m a -16.53% decrease of -1m year over year
  • Acceleron Pharma Long-Term Debt / Capital for the last 12 months ending June 06, 2020 was $4m a -16.53% decrease of -1m year over year
  • Acceleron Pharma Annual Long-Term Debt / Capital for 2019 was $4m a 52,141.75% increase of 2,213m from 2018
  • Acceleron Pharma Annual Long-Term Debt / Capital for 2012 was $-2,209m
Other Ratios Metrics:
  • Acceleron Pharma Total Debt / Capital for the quarter ending December 12, 2013 was $23m a -6,253.89% decrease of -1,413m year over year
  • Acceleron Pharma Other Liabilities for the quarter ending December 12, 2018 was $4m a 14.46% increase of 1m year over year
  • Acceleron Pharma Total Debt / Equity for the quarter ending December 12, 2013 was $29m
View Chart On Koyfin

Quarterly XLRN Long-Term Debt / Capital Data

06/2020$4m
03/2020$4m
12/2019$4m
09/2019$4m
06/2019$4m
03/2019$5m
09/2013$12m
06/2013$85m
03/2013$1,042m
12/2012$-2,209m

Annual XLRN Long-Term Debt / Capital Data

2019$4m
2012$-2,209m